Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 1, 2026, 11:35 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–16 of 16 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Depressive Disorder, Major
Interventions
Rapastinel, Placebo
Drug
Lead sponsor
Naurex, Inc, an affiliate of Allergan plc
Industry
Eligibility
18 Years to 65 Years
Enrollment
465 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
31
States / cities
Beverly Hills, California • Costa Mesa, California • Encino, California + 28 more
Conditions
Depressive Disorder, Major
Interventions
Rapastinel, Placebo
Drug
Lead sponsor
Naurex, Inc, an affiliate of Allergan plc
Industry
Eligibility
18 Years to 65 Years
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
17
States / cities
Birmingham, Alabama • Garden Grove, California • Glendale, California + 14 more
Terminated Phase 3 Interventional Results available

Study of Rapastinel as Monotherapy in Patients With MDD

NCT03560518
Conditions
Depressive Disorder, Major
Interventions
Rapastinel, Placebo
Drug
Lead sponsor
Naurex, Inc, an affiliate of Allergan plc
Industry
Eligibility
18 Years to 75 Years
Enrollment
439 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
40
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Anaheim, California + 34 more
Conditions
Depressive Disorder, Major
Interventions
Rapastinel, Placebo
Drug
Lead sponsor
Naurex, Inc, an affiliate of Allergan plc
Industry
Eligibility
18 Years to 65 Years
Enrollment
658 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
66
States / cities
Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 56 more
Conditions
Major Depressive Disorder
Interventions
GLYX-13
Drug
Lead sponsor
Naurex, Inc, an affiliate of Allergan plc
Industry
Eligibility
18 Years to 65 Years
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Evanston, Illinois
Conditions
Healthy
Interventions
GLYX-13, IV normal saline
Drug
Lead sponsor
Naurex, Inc, an affiliate of Allergan plc
Industry
Eligibility
18 Years to 55 Years
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2015
U.S. locations
1
States / cities
Pasadena, California
Conditions
Depressive Disorder, Major
Interventions
Rapastinel, Placebo
Drug
Lead sponsor
Naurex, Inc, an affiliate of Allergan plc
Industry
Eligibility
18 Years to 75 Years
Enrollment
363 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
40
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Anaheim, California + 34 more
Completed Phase 1 Interventional Accepts healthy volunteers

Assessment of Effect of Rapastinel on Driving Performance

NCT03814733
Conditions
Driving Performance
Interventions
Rapastinel, Alprazolam, Ketamine, Rapastinel Matched Placebo, Alprazolam Matched Placebo, Ketamine Matched Placebo
Drug
Lead sponsor
Naurex, Inc, an affiliate of Allergan plc
Industry
Eligibility
21 Years to 65 Years
Enrollment
107 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
San Clemente, California
Conditions
Depressive Disorder, Major
Interventions
Rapastinel, Placebo-matching Rapastinel
Drug
Lead sponsor
Naurex, Inc, an affiliate of Allergan plc
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
137
States / cities
Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 112 more
Conditions
Obsessive-Compulsive Disorder (OCD)
Interventions
Rapastinel (formerly GLYX-13)
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 55 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
New York, New York
Conditions
Psychiatric Illness, Healthy
Interventions
GLYX-13, Placebo
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 40 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Depressive Disorder, Major
Interventions
Rapastinel
Drug
Lead sponsor
Naurex, Inc, an affiliate of Allergan plc
Industry
Eligibility
18 Years to 65 Years
Enrollment
617 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
128
States / cities
Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 104 more
Conditions
Depressive Disorder, Major
Interventions
Rapastinel
Drug
Lead sponsor
Naurex, Inc, an affiliate of Allergan plc
Industry
Eligibility
18 Years to 75 Years
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
74
States / cities
Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 67 more
Conditions
Depressive Disorder, Major
Interventions
Rapastinel, Placebo
Drug
Lead sponsor
Naurex, Inc, an affiliate of Allergan plc
Industry
Eligibility
18 Years to 65 Years
Enrollment
429 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
40
States / cities
Dothan, Alabama • Phoenix, Arizona • Imperial, California + 34 more
Completed Phase 1 Interventional Accepts healthy volunteers

Assessment of Abuse Potential of Rapastinel in Humans

NCT03799900
Conditions
Human Abuse Potential
Interventions
Rapastinel, Ketamine, Placebo
Drug
Lead sponsor
Naurex, Inc, an affiliate of Allergan plc
Industry
Eligibility
18 Years to 55 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Overland Park, Kansas
Terminated Phase 2 Interventional Results available

Open Label Extension for GLYX13-C-202, NCT01684163

NCT02192099
Conditions
Major Depressive Disorder
Interventions
Rapastinel (225 mg/450 mg IV administration)
Drug
Lead sponsor
Naurex, Inc, an affiliate of Allergan plc
Industry
Eligibility
18 Years to 75 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
10
States / cities
Birmingham, Alabama • San Diego, California • Chicago, Illinois + 7 more